The role and mechanism of rosiglitazone in endothelial-to-mesenchymal transition in pulmonary hypertension

Aoxue Yuan, Yaqian Bai, Yuanhang Jiang, Shengnan Si, Pengwei Wang, Fanrong Zhao, Yujing Chen, Tiantian Zhu

Open source

DOI
10.1016/j.ejphar.2026.179227
Published
2026-10
Container
European Journal of Pharmacology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ejphar.2026.179227,
  title = {The role and mechanism of rosiglitazone in endothelial-to-mesenchymal transition in pulmonary hypertension},
  author = {Aoxue Yuan and Yaqian Bai and Yuanhang Jiang and Shengnan Si and Pengwei Wang and Fanrong Zhao and Yujing Chen and Tiantian Zhu},
  year = {2026},
  journal = {European Journal of Pharmacology},
  doi = {10.1016/j.ejphar.2026.179227},
  url = {https://doi.org/10.1016/j.ejphar.2026.179227}
}

RIS

TY  - JOUR
TI  - The role and mechanism of rosiglitazone in endothelial-to-mesenchymal transition in pulmonary hypertension
AU  - Aoxue Yuan
AU  - Yaqian Bai
AU  - Yuanhang Jiang
AU  - Shengnan Si
AU  - Pengwei Wang
AU  - Fanrong Zhao
AU  - Yujing Chen
AU  - Tiantian Zhu
PY  - 2026
JO  - European Journal of Pharmacology
DO  - 10.1016/j.ejphar.2026.179227
UR  - https://doi.org/10.1016/j.ejphar.2026.179227
ER  - 

APA

Yuan, A., Bai, Y., Jiang, Y., Si, S., Wang, P., Zhao, F., Chen, Y., & Zhu, T. (2026). The role and mechanism of rosiglitazone in endothelial-to-mesenchymal transition in pulmonary hypertension. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.179227

Source records